tbuckley/cabot-search huggingface dataset:
The cognitive science of eyewitness memory
Authors: Laura Mickes, Brent M Wilson, John T Wixted
Journal: Trends in Cognitive Sciences (2025)

Recent insights from cognitive science have reshaped our understanding of the reliability of eyewitness memory. Many believe that eyewitness memory is unreliable, but a better way of thinking is that eyewitness memory, like other types of forensic evidence, can be contaminated. Because contaminated evidence yields unreliable results, the focus should be placed on testing uncontaminated memory evidence collected early in a police investigation. The recent application of theories, principles, and methods from cognitive science has revealed that, both in the laboratory and in the real world, the first test of uncontaminated memory provides much more reliable information than was previously thought. Moreover, and crucially, this reliable but often-ignored evidence frequently points in the direction of a convicted defendant's innocence.
A micro-metabolic rewiring assay for assessing hypoxia-associated cancer metabolic heterogeneity
Authors: Jeong Min Oh, Tianze Guo, Hydari Masuma Begum, Saci-Elodie Marty, Liang Sha, Cem Kilic, Hao Zhou, Yali Dou, Keyue Shen
Journal: Bioactive Materials (2025)
Diagnostic accuracy of 16S rDNA PCR, Multiplex PCR and Metagenomic Next-Generation Sequencing in Periprosthetic Joint Infections: A Systematic Review and Meta-Analysis
Authors: Flaminia Olearo, Said El Zein, Portillo M Eugenia, Antonia Zapf, Holger Rohde, Elie F Berbari, Marjan Wouthuyzen-Bakker
Journal: Clinical Microbiology and Infection (2025)

The diagnostic accuracy of 16S rDNA PCR, multiplex PCR (mPCR), and metagenomic next-generation sequencing (mNGS) in periprosthetic joint infections (PJIs) remains unclear. To evaluate the diagnostic accuracy of 16S rDNA PCR, mPCR, and mNGS in PJI. PubMed and EMBASE (January 1, 2000-March 1, 2024), with no language restrictions. Studies containing sufficient data to construct a 2×2 contingency table allowing for sensitivity and specificity calculation were considered. Adults (≥18 years) with PJI and appropriate control groups. 16S rDNA PCR, mPCR, and mNGS. Diagnosis required adherence to Musculoskeletal Infection Society, Infectious Diseases Society of America (IDSA), International Consensus Meeting, European Bone and Joint Infection Society criteria. Studies employing alternative author-defined criteria were included only if they did not rely solely on positive cultures to define PJI. QUADAS-2 was used. A bivariate model calculated pooled diagnostic odds ratios (DORs), sensitivities, and specificities, each with 95% confidence intervals (CIs). Seventy-nine studies were included, comprising 3,940 PJI cases and 4,700 uninfected controls. Pooled sensitivity/specificity were 80.0% (95% CI: 75.4-84.3%)/94.0% (95% CI: 91-96%) for 16S rDNA PCR; 62.2% (52.5-70.9%)/96.2% (93.2-97.9%) for mPCR; and 88.6% (83.3-92.4%)/93.2% (89.5-95.6%) for mNGS. Notably, mNGS had the highest DOR (105.9; 95% CI: 60-186.9). A sensitivity analysis excluding lower-quality studies resulted in increased DORs for all methods. These molecular techniques display strong diagnostic accuracy for identifying PJI. Although mNGS yielded the highest DOR, numerous technical and practical challenges preclude its routine use for PJI diagnosis. Significant heterogeneity across studies warrants cautious interpretation and underscores the need for future comparative research.
Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
Authors: Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S Lee, Ahmed O Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A Curran, Ji Hoon Kim, Ju-Seog Lee
Journal: Clinical and Molecular Hepatology (2025)

Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Clin Mol Hepatol 2024;30:807-823]
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents
Authors: Tom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, Jannemieke Carbaat-Ham, Mona M. H. E. Fayed, Willemijn J. Scholten, Tim R. Mocking, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Costa Bachas, Gerwin Huls, David C. de Leeuw, Jacqueline Cloos
Journal: Leukemia (2025)
A deep learning based ultrasound diagnostic tool driven by 3D visualization of thyroid nodules
Authors: Yahan Zhou, Chen Chen, Jincao Yao, Jiabin Yu, Bojian Feng, Lin Sui, Yuqi Yan, Xiayi Chen, Yuanzhen Liu, Xiao Zhang, Hui Wang, Qianmeng Pan, Weijie Zou, Qi Zhang, Lu Lin, Chenke Xu, Shengxing Yuan, Qingquan He, Xiaofan Ding, Ping Liang, Vicky Yang Wang, Dong Xu
Journal: npj Digital Medicine (2025)

Recognizing the limitations of computer-assisted tools for thyroid nodule diagnosis using static ultrasound images, this study developed a diagnostic tool utilizing dynamic ultrasound video, namely Thyroid Nodules Visualization (TNVis), by leveraging a two-stage deep learning framework that involved three-dimensional (3D) visualization. In this multicenter study, 4569 cases were included for framework development, and data from seven hospitals were employed for diagnostic validation. TNVis achieved a Dice similarity coefficient of 0.90 after internal testing. For the external validation, TNVis significantly improved radiologists' performance, reaching an AUC of 0.79, compared to their diagnostic performance without the use of TNVis (AUC: 0.66; p < 0.001) and those with partial assistance (AUC: 0.72; p < 0.001). In conclusion, the TNVis-assisted diagnostic strategy not only significantly improves the diagnostic ability of radiologists but also closely imitates their clinical diagnostic procedures and provides them with an objective 3D representation of the nodules for precise and personalized diagnosis and treatment planning.
Porphyromonas gingivalis potentiates stem-like properties of oral squamous cell carcinoma by modulating SCD1-dependent lipid synthesis via NOD1/KLF5 axis
Authors: Wenli Zang, Fengxue Geng, Junchao Liu, Zengxu Wang, Shuwei Zhang, Yuchao Li, Ze Lu, Yaping Pan
Journal: International Journal of Oral Science (2025)

Abstract Cancer stem cells (CSCs) are widely acknowledged as primary mediators to the initiation and progression of tumors. The association between microbial infection and cancer stemness has garnered considerable scholarly interest in recent years. Porphyromonas gingivalis ( P. gingivalis ) is increasingly considered to be closely related to the development of oral squamous cell carcinoma (OSCC). Nevertheless, the role of P. gingivalis in the stemness of OSCC cells remains uncertain. Herein, we showed that P. gingivalis was positively correlated with CSC markers expression in human OSCC specimens, promoted the stemness and tumorigenicity of OSCC cells, and enhanced tumor formation in nude mice. Mechanistically, P. gingivalis increased lipid synthesis in OSCC cells by upregulating the expression of stearoyl-CoA desaturase 1 (SCD1) expression, a key enzyme involved in lipid metabolism, which ultimately resulted in enhanced acquisition of stemness. Moreover, SCD1 suppression attenuated P. gingivalis -induced stemness of OSCC cells, including CSCs markers expression, sphere formation ability, chemoresistance, and tumor growth, in OSCC cells both in vitro and in vivo. Additionally, upregulation of SCD1 in P. gingivalis -infected OSCC cells was associated with the expression of KLF5, and that was modulated by P. gingivalis- activated NOD1 signaling. Taken together, these findings highlight the importance of SCD1-dependent lipid synthesis in P. gingivalis- induced stemness acquisition in OSCC cells, suggest that the NOD1/KLF5 axis may play a key role in regulating SCD1 expression and provide a molecular basis for targeting SCD1 as a new option for attenuating OSCC cells stemness.
Large Vessel Vasculitis on 18F-FDG PET/CT in a Patient With Sarcoidosis
Authors: Raksha Kulkarni, Sampanna Jung Rayamajhi, Vipashyana Jadav, Rahman Akinlusi, Nasrin Ghesani
Journal: Clinical Nuclear Medicine (2025)

Large vessel vasculitis is a rarely reported finding in patients with sarcoidosis. 18 F-FDG PET/CT is an effective modality in detecting active sites of inflammation in sarcoidosis. We present a case of systemic sarcoidosis where 18 F-FDG PET/CT incidentally detected a rare finding of sarcoid-associated large vessel vasculitis along with cardiac and pulmonary sarcoidosis.
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
Authors: Stephen J Freedland, John P Mulhall, Martin Gleave, Ugo De Giorgi, Fred Saad, Antti Rannikko, Jasmina I Ivanova, Anchen F Nasr, Arlene L Reisman, Arijit Ganguli, Pavol Kral, James Turnbull, Neal Shore
Journal: European Urology (2025)
Enhancing Antimicrobial stewardship: recommendations to support implementation of the 2024 UNGA Political Declaration on Antimicrobial Resistance
Authors: F Medioli, N Peiffer-Smadja, L Catteau, R Murri, J A Schouten, K Thursky, M G J de Boer, D Ashiru-Oredope
Journal: Clinical Microbiology and Infection (2025)
GRK2 activates TRAF2–NF-κB signalling to promote hyperproliferation of fibroblast-like synoviocytes in rheumatoid arthritis
Authors: Chenchen Han, Liping Jiang, Weikang Wang, Shujun Zuo, Jintao Gu, Luying Chen, Zhuo Chen, Jiajie Kuai, Xuezhi Yang, Liang Xu, Yang Ma, Wei Wei
Journal: Acta Pharmaceutica Sinica B (2025)
Functional reprogramming of neutrophils within the brain tumor microenvironment by hypoxia-driven histone lactylation
Authors: Alessio Ugolini, Alessandra De Leo, Xiaoqing Yu, Fabio Scirocchi, Xiaoxian Liu, Barbara Peixoto, Delia Scocozza, Angelica Pace, Michela Perego, Alessandro Gardini, Luca D'Angelo, James K C. Liu, Arnold B. Etame, Aurelia Rughetti, Marianna Nuti, Antonio Santoro, Michael A. Vogelbaum, Jose R. Conejo-Garcia, Paulo C. Rodriguez, Filippo Veglia
Journal: Cancer Discovery (2025)

Abstract Despite functional heterogeneity, high frequency of intratumoral neutrophils predicts poor clinical outcomes. The tumor microenvironment reprograms neutrophils into immunosuppressive subsets that hinder anti-cancer immunity, thereby contributing to tumor growth and resistance to immunotherapies. However, the mechanisms underlying neutrophil reprogramming remain elusive. Here, we report that the immunosuppressive ability of brain tumor-infiltrating neutrophils was restricted to a highly glycolytic and long-lived subset expressing CD71, which acquired immunosuppressive properties in response to hypoxia. Mechanistically, hypoxia boosted glucose metabolism in CD71+neutrophils, leading to high lactate production. Lactate caused histone lactylation, which subsequently regulated arginase-1 expression, required for T cell suppression. Targeting histone lactylation with the anti-epileptic drug isosafrole blocked CD71+neutrophil immunosuppressive ability, delayed tumor progression and sensitized brain tumors to immunotherapy. A distinctive gene signature characterizing immunosuppressive CD71+neutrophils correlated with adverse clinical outcomes across diverse human malignancies. This study identifies histone lactylation as a potential therapeutic target to counteract neutrophil-induced immunosuppression within tumors.
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
Authors: Dwight H. Owen, Nofisat Ismaila, Amith Ahluwalia, Jill Feldman, Shirish Gadgeel, Michael Mullane, Jarushka Naidoo, Carolyn J. Presley, Joshua E. Reuss, Eric K. Singhi, Jyoti D. Patel
Journal: Journal of Clinical Oncology (2025)

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and 2 ). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3
Authors: Natasha B. Leighl, Nofisat Ismaila, Greg Durm, Narjust Florez, Janet Freeman-Daily, Bruna Pellini, Deebya Raj Mishra, Erin L. Schenk, Lecia Sequist, Navneet Singh, Lyudmila Bazhenova
Journal: Journal of Clinical Oncology (2025)

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and 2 ). Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline .
Differential risk assessment in persons at risk of type 2 diabetes using urinary peptidomics
Authors: Anja Schork, Andreas Fritsche, Erwin D Schleicher, Andreas Peter, Martin Heni, Norbert Stefan, Reiner Jumpertz von Schwartzenberg, Martina Guthoff, Harald Mischak, Justyna Siwy, Andreas L Birkenfeld, Robert Wagner
Journal: Metabolism (2025)
Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study
Authors: Patrick M Meyer Sauteur, Xu-Sheng Zhang, Hanne-Dorthe Emborg, Semjon Sidorov, Sabine Pereyre, Adrien Fischer, Baptiste Lemaire, Gilbert Greub, Petra Zimmermann, Philipp K A Agyeman, Michael Buettcher, Valeria Gaia, Frank Imkamp, Christoph Berger, Ester Osuna, Beat M Greiter, Benjamin Preiswerk, Silvio D Brugger, Anita Niederer-Loher, Florence Barbey, Branislav Ivan, Sören L Becker, Cihan Papan, Johannes Forster, Birgit Henrich, Malik Aydin, Roger Dumke, Claire Brugerolles, Veerle Matheeussen, Mireille van Westreenen, Steven F L van Lelyveld, Baharak Afshar, Simon Cottrell, Karolina Gullsby, Santtu Heinonen, Miia Laine, Henrik Døllner, Danilo Buonsenso, Daniele Dona, Fernanda Maria Pereira Rodrigues, Jorge Rodrigues, Federico Martinón-Torres, Darja Keše, Marija Gužvinec, Katerina Tsantila, Eleni Kalogera, Hila Elinav, Adong Shen, Yaodong Zhang, Jing Bi, Pei Wang, Kunling Shen, Zhengrong Chen, Ki Wook Yun, Hyunju Lee, Mi Seon Han, Tomohiro Oishi, Takeshi Saraya, Tsutomu Yamazaki, Yu-Chia Hsieh, Tsung-Hua Wu, Matthias Maiwald, Rama Chaudhry, Manish Sadarangani, Larry K Kociolek, Kami D Kies, Lilliam Ambroggio, Nadia Maria Rodriguez, David Lorenz, Matthew R Blakiston, Tsuyoshi Kenri, Ran Nir-Paz, Cécile Bébéar, Annemarie M C van Rossum, Søren Anker Uldum, Michael L Beeton
Journal: The Lancet Microbe (2025)
Re: Valeria Panebianco, Alberto Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in the Management of Patients with Bladder Cancer: Vision of the American College of Radiology VI-RADS Steering Committee. Eur Urol 2024;86:485–7
Authors: Francesco Montorsi, Giuseppe Rosiello, Pietro Scilipoti, Marco Moschini, Andrea Salonia
Journal: European Urology (2025)
Decoding functional hematopoietic progenitor cells in the adult human lung
Authors: Catharina Conrad, Melia Magnen, Jessica Tsui, Harrison Jacob Wismer, Mohammad Naser, Urmila Venkataramani, Bushra Samad, Simon J Cleary, Longhui Qiu, Jennifer J Tian, Marco De Giovanni, Nicole Mende, Andrew D Leavitt, Emmanuelle Passegue, Elisa Laurenti, Alexis J Combes, Mark R. Looney
Journal: Blood (2025)
Macrophage Differentiation and Metabolic Adaptation in Mycobacterial Infections
Authors: Anne Kathrin Lösslein, Philipp Henneke
Journal: Annual Review of Immunology (2025)

The adaptation of macrophages—the most common tissue-resident immune cells—to metabolic and microbial cues with high local variability is essential for the maintenance of organ integrity. In homeostasis, macrophages show largely predictable tissue-specific differentiation, as recently revealed by multidimensional methods. However, chronic infections with human-adapted pathogens substantially contribute to the differentiation complexity of tissue macrophages, which has been only partially resolved. Specifically, the response to mycobacterial species—which range from Mycobacterium tuberculosis (with highest specificity for humans, broad organ tropism, yet tissue-specific disease phenotypes) to environmental mycobacteria with humans as accidental hosts—may serve as a paradigm of tissue macrophage adaptation mechanisms. While mycobacterial species-specific tissue preferences are partially related to the mode of acquisition and pathogen characteristics, evolutionary convergence with macrophages driven by metabolic features of the target organ likely contributes to infection resistance and immunopathology. In this review, we unravel the mechanisms of tissue-specific macrophage differentiation and its limitations in mycobacterial infections.
Roles of Sirtuins in Cardiovascular Diseases: Mechanisms and Therapeutics
Authors: Yang-Nan Ding, Hui-Yu Wang, Xiao-Feng Chen, Xiaoqiang Tang, Hou-Zao Chen
Journal: Circulation Research (2025)

Cardiovascular diseases (CVDs) are experiencing a rapid surge and are widely recognized as the leading cause of mortality in the current aging society. Given the multifactorial etiology of CVDs, understanding the intricate molecular and cellular mechanisms is imperative. Over the past 2 decades, many scientists have focused on Sirtuins, a family of nicotinamide adenine dinucleotide–dependent deacylases. Sirtuins are highly conserved across species, from yeasts to primates, and play a crucial role in linking aging and diseases. Sirtuins participate in nearly all key physiological and pathological processes, ranging from embryogenic development to stress response and aging. Abnormal expression and activity of Sirtuins exist in many aging-related diseases, while their activation has shown efficacy in mitigating these diseases (eg, CVDs). In terms of research, this field has maintained fast, sustained growth in recent years, from fundamental studies to clinical trials. In this review, we present a comprehensive, up-to-date discussion on the biological functions of Sirtuins and their roles in regulating cardiovascular biology and CVDs. Furthermore, we highlight the latest advancements in utilizing Sirtuin-activating compounds and nicotinamide adenine dinucleotide boosters as potential pharmacological targets for preventing and treating CVDs. The key unresolved issues in the field—from the chemicobiological regulation of Sirtuins to Sirtuin-targeted CVD investigations—are also discussed. This timely review could be critical in understanding the updated knowledge of Sirtuin biology in CVDs and facilitating the clinical accessibility of Sirtuin-targeting interventions.
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Authors: Sunil V. Rao, Michelle L. O’Donoghue, Marc Ruel, Tanveer Rab, Jaqueline E. Tamis-Holland, John H. Alexander, Usman Baber, Heather Baker, Mauricio G. Cohen, Mercedes Cruz-Ruiz, Leslie L. Davis, James A. de Lemos, Tracy A. DeWald, Islam Y. Elgendy, Dmitriy N. Feldman, Abhinav Goyal, Ijeoma Isiadinso, Venu Menon, David A. Morrow, Debabrata Mukherjee, Elke Platz, Susan B. Promes, Sigrid Sandner, Yader Sandoval, Rachel Schunder, Binita Shah, Jason P. Stopyra, Amy W. Talbot, Pam R. Taub, Marlene S. Williams, Hani Jneid, Craig J. Beavers, Theresa Beckie, Jim Blankenship, Deborah Diercks, Bruce Lo, Clauden Louis, Faisal M. Merchant, Noreen T. Nazir, Derek So, Matthew Tomey, Frederick Welt
Journal: Journal of the American College of Cardiology (2025)
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Authors: Sunil V. Rao, Michelle L. O’Donoghue, Marc Ruel, Tanveer Rab, Jaqueline E. Tamis-Holland, John H. Alexander, Usman Baber, Heather Baker, Mauricio G. Cohen, Mercedes Cruz-Ruiz, Leslie L. Davis, James A. de Lemos, Tracy A. DeWald, Islam Y. Elgendy, Dmitriy N. Feldman, Abhinav Goyal, Ijeoma Isiadinso, Venu Menon, David A. Morrow, Debabrata Mukherjee, Elke Platz, Susan B. Promes, Sigrid Sandner, Yader Sandoval, Rachel Schunder, Binita Shah, Jason P. Stopyra, Amy W. Talbot, Pam R. Taub, Marlene S. Williams
Journal: Circulation (2025)

Aim: The “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes” incorporates new evidence since the “2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction” and the corresponding “2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes” and the “2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction.” The “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes” and the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization” retire and replace, respectively, the “2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease.” Methods: A comprehensive literature search was conducted from July 2023 to April 2024. Clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants were identified that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Structure: Many recommendations from previously published guidelines have been updated with new evidence, and new recommendations have been created when supported by published data.